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“French type” sialuria, a presumably dominant disorder that, until now, had been documented in only five patients,
manifests with mildly coarse facies, slight motor delay, and urinary excretion of large quantities (11 g/d) of free
N-acetylneuraminic acid (NeuAc). The basic defect consists of the very rare occurrence of failed feedback inhibition
of a rate-limiting enzyme, in this case uridinediphosphate-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase, by a
downstream product, in this case cytidine monophosphate (CMP)–NeuAc. We report a new patient with sialuria
who has a heterozygous GrA substitution in nucleotide 848 of the epimerase gene, which results in an R266Q
change. The proband’s other allele, as expected, had no mutation. However, the heterozygous R266Q mutation
was detected in the patient’s mother, who has similarly increased urinary levels of free NeuAc, thereby confirming,
for the first time, the dominant mode of inheritance of this inborn error. The biochemical diagnosis of the proband
was verified by the greatly increased level of free NeuAc in his cultured fibroblasts, the NeuAc distribution, mainly
(59%) in the cytoplasm, and by the complete failure of 100 mM CMP-NeuAc to inhibit UDP-GlcNAc 2-epimerase
activity in the mutant cells. These findings call for expansion of the phenotype to include adults and for more-
extensive assaying of free NeuAc in the urine of children with mild developmental delay. The prevalence of sialuria
is probably grossly underestimated.
Introduction
“French type” sialuria (MIM 269921) is a rare human
metabolic disorder caused by failed feedback inhibition
of a catalytically normal enzyme (Weiss et al. 1989; Sep-
pala et al. 1991). The enzyme is uridinediphosphate-N-
acetylglucosamine (UDP-GlcNAc) 2-epimerase, which is
rate limiting in the synthesis of sialic acid or N-acetyl-
neuraminic acid (NeuAc). The allosteric feedback inhib-
itor is cytidine monophosphate-N-acetylneuraminic acid
(CMP-Neu5Ac) (Kornfeld et al. 1964; Sommar and Ellis
1972), which also donates sialic acid for the synthesis
of sialylglycoconjugates (Aula and Gahl 2001). The lack
of feedback inhibition of UDP-GlcNAc 2-epimerase re-
sults in vastly increased urinary excretion of free NeuAc
(Thomas et al. 1985; Gahl et al. 1996). Although the
first patient with sialuria was reported in France 130
years ago (Fontaine et al. 1968; Montreuil et al. 1968),
molecular characterization of this type of sialuria was
only recently accomplished (Seppala et al. 1999). Be-
cause an entirely normal coding sequence was demon-
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strated in one allele of each patient investigated, sialuria
was proposed to be inherited in a dominant fashion.
To date, five patients have been reported with sialuria
(Fontaine et al. 1968; Wilcken et al. 1987; Seppala et
al. 1991; Krasnewich et al. 1993; Ferreira et al. 1999);
most have mild developmental delay and coarse facial
features but no other physical signs of a storage disorder.
In the present report, we provide a detailed clinical,
biochemical, and molecular report of the sixth (Leroy
et al. 1998) and seventh patients with sialuria, a boy
and his mother. These patients confirm, for the first time,
the autosomal dominant nature of the disorder and ex-
pand the clinical phenotype of this inborn error. The
results indicate that the prevalence of sialuria may be
grossly underestimated and that diagnostic evaluations
of appropriate individuals should be performed more
frequently.
Subjects and Methods
Clinical Reports
Patient 1.—The boy was born, after 35 weeks of ges-
tation, to an unaffected 30-year-old woman, by normal
vertex delivery. The 32-year-old father was unrelated to
the mother. Two older brothers were unaffected. Birth
length was 44 cm, and occipitofrontal circumference
(OFC) was 33 cm. Because of mild grunting, hypotonia,
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Figure 1 Clinical features in patient 1. A and B, Proband at age
10.5 mo. Note flat, mildly coarse facies, epicanthal folds, and low
nasal bridge; excessive nasal discharge; difficulty sitting without sup-
port; and mild axial hypotonia. C and D, Proband at age 4 years. The
patient is considerably improved, with significant neuromotor pro-
gress. Note accidental scar on nose, absence of facial coarsening, and
no limitation of motion in any joints.
Figure 2 Skeletal radiographs of proband at age 10.5 mo. Note
slightly short and wide long-bone diaphyses; squat pubic and ischial
bones; osteopenic, mildly short, and coarsely trabeculated metacarpals;
and widened metaphyses in the distal ulnae and radii, distal femora,
and proximal tibiae. The skeletal age was between 3 and 6 mo.
and low birth weight (2,350 g), the newborn infant spent
one week in an incubator and received oxygen. He had
prolonged mild jaundice. At 2 mo of age, frequent opis-
thotonic posturing and persistent hypotonia were no-
ticed. Anemia was treated with a transfusion of packed
red blood cells. At 3 mo of age, a CT scan of the brain
showed a widened interhemispheric fissure and widened
cortical sulci but did not show any anatomic or textural
abnormalities. Excessive rhinorrhea and recurrent res-
piratory infections were present throughout infancy.
At 10 mo of age, failure to thrive (FTT) was docu-
mented, and a storage disorder was suspected because
of poor growth, coarse facial features, and a new viral
infection with dehydration that required hospital ad-
mission. Weight and length were 7,340 g and 68 cm,
respectively, and the OFC was 45.5 cm. The patient re-
mained hypotonic but was alert and grasped objects. He
crawled and was able to sit and stand with support. The
head was scaphocephalic, and the facies was flat and
plump. There was mild proptosis of the eyes, a low nasal
bridge, and epicanthal folds (fig. 1A and 1B). There was
no organomegaly or lymphadenopathy. The range of
motion was full in all joints, including the shoulders.
Deep-tendon reflexes were symmetrically weak. Radio-
graphs showed mildly shortened and broad diaphyses of
long bones, squat pubic and ischial bones, and slightly
shortened and widened osteopenic metacarpals (fig. 2).
The skeletal age was between 3 and 6 mo.
Results of routine urine screening were normal for
glycosaminoglycans and neutral and charged oligosac-
charides. Erythrocyte and leukocyte counts (total and
differential) were normal. Frank microcytic hypochrom-
ic anemia was successfully treated with a transfusion of
packed red blood cells. Results of thyroid-function tests
in serum were within normal limits. The specific activ-
ities of several lysosomal acid hydrolases in serum were
either normal or two to three times the value in age-
matched controls. The corresponding activities in leu-
kocytes and fibroblasts were normal, but the activity of
b-D-galactosidase was double that in controls. Urinary
concentration of free sialic acid was 14,680 mmol/mmol
creatinine (control !74 mmol/mmol). A skin biopsy was
performed.
Impaired hip and knee extensions were noted at age
15 mo. The boy remained hypotonic but alert and phys-
ically active. At 32 mo, his neuromotor and physical
development had progressed significantly, and his weight
was 12 kg (3d–10th percentile), his length was 93 cm
(25th–50th percentile), and his OFC was 49.9 cm
(25th–50th percentile). The liver edge was felt 2 cm be-
low the costal margin. He had started walking alone at
2 years of age but maintained a broadly based gait. He
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spoke several words but made no two-word sentences.
Grasping remained primitive, and social contacts were
elementary. The boy was briefly admitted to hospital for
a tonsillectomy and adenoidectomy. The enlarged ton-
sils, described as unusually pale, were examined histo-
logically. At age 38 mo, a psychometric evalua-
tion—using the McCarthy Scales of Children’s Abilities,
the motor part of the Bayley Scales of Infant Develop-
ment, and the Raynell Language Scale—yielded a general
cognitive index of 70, which is consistent with borderline
mental handicap that manifested primarily as delayed
development of language and motor skills.
When the proband was seen shortly after his fourth
birthday, his general health had improved considerably.
He weighed 15 kg (∼25%). His height was 99.3 cm
(10th–25th percentile), and his OFC was 50.4 cm (∼50
percentile) (fig. 1C and 1D). There was no organome-
galy, and respiratory infections had become mild and
infrequent. The lumbar spine was slightly hyperlordotic
and was associated with minimal flexion contracture in
both hips. The knees were held in mild flexion. No neu-
rologic abnormality was found. The skeletal age was
between 2.5 and 3 years. At age 4 years and 8 mo the
urinary level of free NeuAc was 8,950 mmol/mmol
creatinine.
Patient 2.—This 34-year-old woman, the mother of
patient 1, was a healthy homemaker of normal stature
without dysmorphic features. Like her sole brother,
she had completed only regular grade school. In con-
trast, all four of her sisters graduated from various
college-level training programs. The patient briefly
held domestic employment before marriage. Additional
objective data on her early-childhood development, neu-
romotor status, and results of psychometric testing were
not available. After patient 2 was found to manifest the
same UDP-GlcNAc 2-epimerase gene mutation as her
son, her urinary level of free NeuAc was found to be
4,278 mmol/mmol creatinine (control !74 mmol/mmol)
or 48 mmol/mg creatinine. The urinary levels of free
NeuAc in the father of patient 1, in the father and all
five sibs of patient 2, and in the two older brothers of
patient 1 were normal. The maternal grandmother had
died of liver cancer at the age of 49 years.
Cellular and Biochemical Studies
Fibroblasts were cultured, and their subcellular frac-
tions were prepared as described elsewhere (Seppala et
al. 1991). Assay of free NeuAc in urine and whole-cell
homogenates was performed according to the method
of Cardo et al. (1985). For analysis of subcellular frac-
tions and lymphoid tissue, free NeuAc was determined
using anion-exchange chromatography with a Dionex
AS6-Ion-Pack column, followed by quantitation using
pulsed amperometric detection (Dionex Bio), as de-
scribed elsewhere (Seppala et al. 1991). Specific activities
of lysosomal enzymes in plasma, leukocytes, and fibro-
blasts were determined as reported elsewhere (Leroy et
al. 1972). UDP-GlcNAc 2-epimerase activity and the de-
gree of inhibition by CMP-sialic acid were studied by
methods published elsewhere (Weiss et al. 1989; Seppala
et al. 1991).
Molecular Investigations
Total RNA was extracted from cultured skin fibro-
blasts, using Trizol reagent (Life Technologies), and was
reverse transcribed to cDNA, using the Superscript First
Strand Synthesis System (Life Technologies). The pa-
tient’s cDNA was screened for mutations in the epi-
merase gene as described by Seppala et al. (1999). Nu-
cleotide numbering is according to GenBank accession
number NM_005476. To confirm the heterozygous
GrA (R266Q) mutation at nucleotide 848, genomic
DNA was isolated from the blood of the proband and
both his parents, using standard techniques (Sambrook
et al. 1989). PCR amplification was employed to obtain
a 385-bp fragment that included the mutation site. The
forward PCR primer (5′-TGAGTTCCTAGATGAGTG-
AAG-3′) was located in the intron between cDNA nu-
cleotides 818 and 819, and the reverse PCR primer (5′-
CAGGTTGATCACAGGTGTT-3′) was located in the
exon (cDNA nucleotides 1005–987) that contains the
mutation site. PCR amplifications were performed under
standard conditions, with a primer-annealing tempera-
ture of 55C. The PCR products were electrophoresed
on 1% agarose that contained ethidium bromide. The
DNA bands were cut from the gel and purified with the
MERmaid spin kit (BIO101).
For direct sequencing, purified DNA served as a tem-
plate in a sequencing-PCR reaction using the BigDye
Terminator Cycle Sequencing Ready Reaction kit, ac-
cording to the manufacturer’s guidelines (PE Applied
Biosystems). Reaction products were ethanol-precipi-
tated, resuspended in formamide loading buffer, and
electrophoresed on an ABI 377 automated sequencer.
For restriction-enzyme digestion, the purified DNA
was incubated for 3 h at 37C with the AciI restriction
enzyme, according to the manufacturer’s recommenda-
tions (New England Biolabs). The digestion products
were then electrophoresed on a 1% agarose gel and
stained with ethidium bromide.
Tissue Analysis
Tonsil and adenoid tissue samples were processed and
studied according to standard procedures for light and
electron microscopy (Martin et al. 1975).
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Table 1
Distribution of Free Sialic Acid in Subcellular Fractions of Fibroblasts
FRACTION
% OF TOTAL
HEXOSAMINIDASEa
RECOVERED
FROM
PATIENT 1
% OF TOTAL FREE NEURAMINIC ACID RECOVERED FROM
Patient 1 Control Patientsb Patients with Sialuriab,c Patients with ISSDc,d
Nuclear 16 13 18 5, 7 5, 6
Lysosomal 81 21 21 4, 3 56, 77
Microsomal 3 7 3 2, 2 29, 80
Soluble 0 59 54 89, 88 10, 10
a N-acetyl-b-D-hexosaminidase (EC 3.2.1.52). Values for patient 1 are consistent with the normal, expected distri-
bution within the subcellular fractions.
b Seppala et al. 1991.
c The two numbers in each cell represent values from repeat experiments.
d Tietze et al. 1989.
Results
Fibroblast Sialic Acid
The cultured fibroblasts of patient 1 were harvested
at the confluent-monolayer–culture stage on the third
day after culture-medium exchange. The free NeuAc
concentration was 36 nmol/mg protein (control !0.1
nmol/mg protein). The free NeuAc in the supernatant
culture medium was 13.6 nmol/mL (control !0.1 nmol/
mL) and 7.4 nmol/mL in the PBS rinse before scraping
the cells. The subcellular distribution of free NeuAc in
the patient’s fibroblasts was characteristic of sialuria.
Although 81% of the total amount of the lysosomal
marker enzyme (hexosaminidase) was present in the ly-
sosomal fraction, only 21% of the recovered NeuAc was
found in the lysosomes, and 59% of the recovered
NeuAc was in the soluble fraction representing the cy-
toplasm (table 1).
Tissue Analysis
In the proband’s tonsillar tissue, the concentration of
free sialic acid was 66.8 nmol/mg protein (control 5.6
nmol/mg protein). Histologically, the tonsil and adenoid
tissues showed no storage phenomena, such as foam cells
or swollen lysosomal inclusions. These findings were
confirmed by electron microscopy, which did not reveal
any morphologic abnormality in the mitochondria or
the endoplasmic reticulum (data not shown). The latter
structures were found to be abnormal in the hepatocytes
of two patients with sialuria who were reported else-
where (Fontaine et al. 1968; Wilcken et al. 1987).
Biochemical and Molecular Diagnoses
The diagnosis of sialuria was confirmed on both bio-
chemical and molecular grounds. First, enzymatic activ-
ity of UDP-GlcNAc 2-epimerase was measured in cul-
tured fibroblasts in the presence and absence of 100 mM
CMP-Neu5Ac. Although the normal fibroblast epimer-
ase activity was 95% inhibited by 100 mM CMP-
Neu5Ac (fig. 3A), the epimerase of patient 1 was not
inhibited at all (fig. 3B). Published levels of inhibition
are 79%–100% for normal fibroblasts and 19%–27%
for sialuria cells (Seppala et al. 1991; Ferreira et al.
1999).
Second, the patient’s epimerase gene was sequenced
and found to contain a heterozygous GrA change in
nucleotide 848 (fig. 4A). The resulting glutamine-for-
arginine substitution in codon 266 has been reported as
the causative mutation in sialuria for two of the five
patients reported elsewhere (Ferreira et al. 1999; Seppala
et al. 1999).
Family Studies
It has been proposed, because of the apparent clinical
normalcy of the patients’ parents, that sialuria is an au-
tosomal dominant disorder and that affected individuals
represent new mutations (Weiss et al. 1989; Seppala et
al. 1991, 1999). We attempted to confirm this by per-
forming molecular analysis of the UDP-GlcNAc 2-epi-
merase gene of the DNA in the parents of patient 1. The
results indicate that the father has two normal epimerase
alleles, but the mother bears the same mutation as her
affected son (fig. 4A).
To verify this finding, we made use of the fact that
the G848A mutation deletes an AciI restriction site. In
normal controls, the 385-bp fragment produced by PCR
amplification of the region will be cut into 229-bp and
156-bp fragments. In contrast, the 385-bp fragment is
retained if the G848A mutation is present. This restric-
tion-enzyme analysis revealed that the patient and his
mother, but not his two unaffected brothers or his father,
carry the heterozygous mutation (fig. 4B).
Discussion
Several pieces of evidence indicate that sialuria repre-
sents a mild disorder whose manifestations overlap the
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Figure 3 CMP-Neu5Ac inhibition of UDP-GlcNAc 2-epimerase
activity. The substrate of epimerase is [3H]UDP-GlcNAc, and the prod-
uct is [3H]ManNAc. [3H]GlcNAc represents a degradation product of
[3H]UDP-GlcNAc, not a product of epimerase (Seppala et al. 1992).
A, Epimerase activity in normal fibroblasts. Significant ManNAc is
formed in the absence of CMP-Neu5Ac (left), and 100 mM CMP-
Neu5Ac inhibits ManNAc formation by 95% (right). B, Fibroblast
epimerase activity in patient 1. CMP-Neu5Ac, 100 mM (right), did
not inhibit ManNAc production at all compared with ManNAc pro-
duction in the absence of CMP-Neu5Ac (left).
Figure 4 Molecular diagnosis of sialuria in the family of patient
1. A, Genomic DNA sequencing of patient 1, his father, and his mother
(patient 2). At position 848, the father has the normal G, but both
the patient and his mother are heterozygous for the GrA substitution.
B, Agarose gel electrophoresis of reaction products formed by AciI
restriction-enzyme digestion of a 385-bp fragment that includes nu-
cleotide 848. Lane 1, molecular weight markers. Lanes 2 and 3, fa-
ther’s DNA, uncut (U) and completely cut (C) into 229-bp and 156-
bp fragments. Lanes 4–7, DNA from the two unaffected siblings, uncut
(lanes 4 and 6) and completely cut (lanes 5 and 7). Lanes 8–11, DNA
from the proband (patient 1) and his mother (patient 2), uncut (lanes
8 and 10) and cut (lanes 9 and 11). The cut DNA shows heterozygosity
for the normal sequence (229-bp and 156-bp fragments) and the mu-
tation (uncut 385-bp fragment).
range of normal. First, patient 1, who is only the sixth
case of “French type” sialuria to be described, displayed
a very mild course between the ages of 10 and 48 mo.
Despite frequent infections in the first 2 years of life, his
primary feature was mild delay of neuromotor devel-
opment. The coarse facial features observed in infancy
(fig. 1A) were transient. Patient 1 remained normo-
cephalic, maintained normal joint mobility, and had only
equivocal hepatomegaly. Except for its delayed ossifi-
cation, the skeleton showed no radiographic abnormal-
ities after the boy was 2 years old. The mild hypotonia
persisted, but patient 1 was an alert child who made
slow but steady progress in speech development.
Descriptions published elsewhere of the five known
patients with sialuria (table 2) provide an additional
rationale for considering sialuria a mild disease. In in-
fancy, sialuria presents only with nonspecific signs and
symptoms, some of which are reminiscent of a lyso-
somal storage disorder. In each recorded case, the preg-
nancy was normal, except for one instance of prema-
turity (Krasnewich et al. 1993). As newborn infants, the
patients were small for their gestational age but had
normal head circumferences. In general, the patients ex-
hibited a flat, coarse facies and mild developmental de-
lay, which, in one patient, was recorded only as con-
genital, persistent hypotonia (Wilcken et al. 1987).
Hepatomegaly was consistently recorded in all patients
but was usually mild and was documented only by clin-
ical examination. Some of the patients experienced fre-
quent upper-respiratory tract infections (UTIs) through-
out infancy and into the second year of life, along with
episodes of gastroenteritis with dehydration and tran-
sient FTT. In two patients, including patient 1 in the
present study, prolonged neonatal jaundice was noted.
The patient reported here and the original French pa-
tient also had microcytic anemia. Children with sialuria
have consistently shown delayed skeletal development,
with few signs of dysostosis multiplex (fig. 2) in the first
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Table 2
Clinical Features of Children with “French Type” Sialuria and Their Mutation in the Epimerase Gene
CHARACTERISTIC
FEATURES OF
Patient 1 Patient 2 Patient 3 Patient 4a Patient 5b Patient 6
Year identified 1968 1987 1989 1993 1999 this report
Sex Male Female Male Male Female Male
Referencec A B C D E F
Pre- and perinatal:
Normal pregnancy      
Normal delivery      
Gestation (weeks) 36 39 40 30 40 35
Anthropometry at birth:
Weight (g) 2,650 2,740 … 1,700 2,650 2,350
Length (cm) … … … … 46 44
OFC (cm) … 34.5 … … 33 33
Signs and symptoms:
Age at examination 4.5 mo Infancy 2 mo Infancy Infancy Infancy
Developmental delay      
Hypotonia …   … … 
Coarse facies      
Hepatomegaly      
Prolonged jaundice   … … … 
Hypochromic anemia  … … … … 
Seizures   …   
Transient FTT   … …  
Frequent UTIs   … …  
Physical development:
Age at examination
(years) 3.5 7.0 5.5 4.5 7.42 4.08
Weight (%)d 10 10–25 … 25–50 75–90 10–25
Height (%)d 3–10 10–25 25–50 25–50 75–90 10–25
OFC (%)d … 97 … 25–50 50–75 25–50
Neuromental assessment:
Age at assessment
(years) 4.17 7 5.5 4.5 7.42 4.08
Developmental age or
IQ 1.42 years 4.58 years Normal 68 78 70
Mutation:
Nucleotide change: sitee … CrT: 849 GrA: 848 GrT: 839 GrA: 848 GrA: 848
Amino acid
substitutionf … R266W R266Q R263L R266Q R266Q
NOTE.—A plus sign () indicates presence, and a minus sign () indicates absence.
a Additional clinical features were mild thoracic scoliosis, enlarged cerebral ventricles, hirsutism, and obstructive sleep apnea.
b Additional clinical features were obstructive sleep apnea and febrile seizures.
c “A” indicates Fontaine et al. 1968. “B” indicates Wilcken et al. 1987; Don et al. 1991; Seppala et al. 1999. “C” indicates Weiss et al.
1989; Seppala et al. 1991; Gahl et al. 1996; “D” indicates Krasnewich et al. 1993; Seppala et al. 1999. “E” indicates Ferreira et al. 1999. “F”
indicates Leroy et al. 1998.
d Numbers represent percentile in cumulative chart of physical development.
e Nucleotide number according to Genbank accession number NM_005476.
f R indicates arginine, W indicates tryptophan, Q indicates glutamine, and L indicates leucine.
years of life. In other respects, physical development has
been normal (table 2). Developmental ages or IQs have
been borderline low in all patients, and the first child
described had moderate retardation. However, later in
childhood, neuromotor and mental development have
been either mildly impaired or almost unaffected, and
two patients attended schools for children without dis-
abilities (Weiss et al. 1989; Krasnewich et al. 1993; Fer-
reira et al. 1999). Therefore, some older patients may
never come to medical attention. Frank seizures, which
were controlled with barbititurates, were observed in
two instances (Fontaine et al. 1968; Wilcken et al.
1987), and the Portuguese girl with sialuria had hy-
perthermic convulsions (Ferreira et al. 1999).
Finally, the concept that sialuria represents a mild
condition after early childhood is supported by the di-
agnosis in the proband’s mother (patient 2). This
woman—the seventh example and the first adult patient
known to have sialuria—was diagnosed retrospectively
and did not consider herself affected in any way. Clearly,
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additional detailed reports are required to definitively
delineate the average and the extreme clinical pheno-
types of sialuria. It is possible that the phenotypes of
patients 1 and 2 are not significantly different, given
the disparate social and educational expectations of the
son’s and the mother’s generations.
In patient 1, the diagnosis of sialuria was confirmed
by the findings of increased urinary excretion of free
NeuAc, typical cytoplasmic distribution of free sialic
acid within cultured fibroblasts, and reduced inhibi-
tion of fibroblast UDP-GlcNAc 2-epimerase by CMP-
Neu5Ac, as well as the detection of a mutation (in the
putative allosteric domain of the UDP-GlcNAc 2-epi-
merase gene) that is known to cause sialuria. Specifi-
cally, the urinary level of free NeuAc was 167 mmol/mg
creatinine, which is slightly above the levels in other
patients with sialuria (range 19–117 mmol/mg creati-
nine) (Ferreira et al. 1999). However, at 4 years and 8
mo of age, the level was found to be 102 mmol/mg
creatinine, which is well within the range of values in
other patients with sialuria. The same conclusion holds
for the urinary excretion of less than half the quantity
(48 mmol/mg creatinine) in the mother. At present, no
factors are known that may be correlated directly with
the amount of free sialic acid in the patients’ urine. Even
the confirmation that age may account for some of the
fluctuation must await prospective studies in more pa-
tients. Similarly, the fibroblast level of free NeuAc (36
nmol/mg protein) was typical of that reported in sialuria
cells (17–273 nmol/mg of protein), and the 59% cyto-
plasmic distribution was also representative of that for
patients with sialuria (Ferreira et al. 1999). In sialuria,
50–100 mM CMP-Neu5Ac inhibits UDP-GlcNAc 2-epi-
merase by 19%–27% (normal 79%–100%), and, in the
proband in the present study, the inhibition was zero
(fig. 3B). Finally, mutation analysis of the UDP-GlcNAc
2-epimerase gene of the proband in the present study
revealed the same R266Q mutation (fig. 4) that was ob-
served in two other patients with sialuria (table 2).
Other diagnoses were systematically eliminated. The
finding of an increased level of sialic acid in the urine
argued against consideration of other storage disorders,
such as the mucopolysaccharidoses or the glycoprotei-
noses. Deficiency of sialidase, or neuraminidase, was
ruled out because the increased NeuAc was free and not
bound in the form of glycoconjugates. Disorders of free
sialic acid storage were more strongly considered. The
increased urinary excretion of free NeuAc was consis-
tent with the diagnosis of infantile free sialic
acid–storage disease (ISSD) (MIM 269920). However,
patients with this progressive encephalopathy, which re-
sults from faulty egress of free sialic acid from lysosomes
(Weiss et al. 1989; Gahl et al. 1996), experience frank
regression of neuromotor and mental development,
alarming neurologic signs, and, occasionally, death in
infancy. Moreover, in ISSD, the free NeuAc accumulates
in cellular lysosomes rather than in the cytoplasm
(Tietze et al. 1989). Patients with Salla disease (MIM
604369), a milder allelic variant of ISSD that is most
often observed in Finland, have a later clinical onset
and a more chronic course; the excess of free sialic acid
in urine is also less pronounced (Gahl et al. 1996). The
diagnosis of Salla disease was ruled out by the proband’s
mild clinical course, by the lack of a lysosomal abnor-
mality in his lymphoid tissue, and by the cytoplasmic
location of the storage of free NeuAc in fibroblasts.
In addition to the progress in its clinical delineation,
the observation and study of the two patients with sial-
uria reported here contribute significantly to current sci-
entific understanding of the disorder. First, the diagnosis
of sialuria in the proband’s mother—which was verified
molecularly, as well as on the basis of vastly increased
urinary excretion of free NeuAc—confirms the domi-
nant mode of inheritance of this disorder. This is in
agreement with the demonstration in this and other pa-
tients (Cardo et al. 1985; Seppala et al. 1999) that only
one of the two alleles of the UDP-GlcNAc 2-epimerase
gene contains a mutation. It also represents the first
instance in which the disorder in a patient with sialuria
is not simply assumed to be the result of a new mutation.
Dominant inheritance in sialuria is supported somewhat
by the lack of parental consanguinity in every instance
reported, and it has a logical basis in the biochemistry
of the disorder. In sialuria, the mutant UDP-GlcNAc 2-
epimerase retains normal catalytic activity; however, un-
like the normal enzyme, it is no longer inhibitable by
CMP-NeuAc binding (Kornfeld et al. 1964; Sommar
and Ellis 1972; Cardo et al. 1985; Thomas et al. 1985;
Seppala et al. 1999) (fig. 3). Thus, even in the hetero-
zygous state, the mutant allele produces a constitutively
active, rate-limiting enzyme that achieves sufficient
NeuAc synthesis to cause overproduction of free sialic
acid. A similar, recently documented example of an in-
born error of metabolism with dominant inheritance
due to failed allosteric inhibition is the syndrome of
hyperinsulinism and hyperammonia in infants who are
heterozygous for a mutation in the allosteric domain of
the glutamate dehydrogenase gene (Stanley et al. 1998).
The failure of allosteric regulation of UDP-GlcNAc
2-epimerase may not be the sole explanation for the
dysregulated synthesis of free NeuAc in sialuria. En-
hanced stability of the enzyme may also contribute to
overproduction of NeuAc (Ferreira et al. 1999). There
is no evidence suggesting this possibility, however, and
the failed feedback inhibition of UDP-GlcNAc 2-epi-
merase activity amply explains the excessive urinary ex-
cretion, the significantly increased levels of NeuAc in
the mutant cultured fibroblasts and in lymphoid tissue,
and the intracellular distribution of NeuAc primarily in
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the cytoplasm, as opposed to its intralysosomal accu-
mulation in ISSD cells (table 1).
A second conclusion to be drawn from the proband’s
family is that the GrA transition in the second nucle-
otide of codon 266 probably represents a real mutation,
not merely a polymorphism. The mutation is exactly
the same as that found in two of the five other patients
with sialuria, and it results in a glutamine-for-arginine
missense substitution (Ferreira et al. 1999; Seppala et
al. 1999). Furthermore, in the family reported here, the
mutation segregates with the disorder (fig. 4B), as in-
dicated by increased urinary excretion of free sialic acid
observed only in the two family members who bear the
mutation. Other reported patients are heterozygous for
a CrT transition in the third nucleotide of codon 266,
resulting in an arginine-to-tryptophan substitution, or
a GrT transversion in the second base of codon 263,
causing an arginine-to-leucine substitution (Seppala et
al. 1999) (table 2). The clustering of all these mutations
in the region of codons 263–266 supports the hypoth-
esis that this stretch of amino acids in the aminoterminal
part of the epimerase gene product is part of the allo-
steric site for CMP-Neu5Ac binding and its normal in-
hibitory feedback action.
Finally, we believe that the prevalence of sialuria may
be underestimated because of its mild phenotype and
the variable increase in NeuAc excretion. Moreover, as-
say of urinary levels of free NeuAc is not a routine
laboratory procedure and is generally performed only
for confirmation or exclusion of the diagnosis of ISSD
or Salla disease in infants or toddlers with progressive
brain disease. We note that the mother of our patient
was never clinically suspected of having sialuria. Con-
sequently, the immediate relatives of known patients
with sialuria should be screened for mutations in codons
263–266 of the UDP-GlcNAc 2-epimerase gene. In ad-
dition, assay of urinary level of free NeuAc could be
part of the metabolic screening of young children with
mild developmental delay.
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